UPDATE: Morgan Stanley Starts Centessa Pharmaceuticals (CNTA) at Overweight

Go back to UPDATE: Morgan Stanley Starts Centessa Pharmaceuticals (CNTA) at Overweight

Centessa Pharmaceuticals (CNTA): Analysts Initiate With 'Buy' on 'Broad Pipeline With Significant Optionality'

June 22, 2021 8:35 AM EDT

Wall Street analysts have kicked off coverage of Centessa Pharmaceuticals (NASDAQ: CNTA) with a rating equivalent to Buy. So far, analysts at Jefferies, Goldman Sachs, and Morgan Stanley are all positive on the stock.

Centessa Pharmaceuticals secured $330 million in an initial public offering (IPO) in May in a bid to continue with its plan of reshaping the traditional drug development process.

The company initially intended to offer 15 million of its depositary shares in the IPO, priced between $18 and $20 per share. However, Contessa later raised the number of offered shares to 16.5 million,... More

Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy

June 22, 2021 1:17 AM EDT

Goldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $42.00.

The analyst comments "CNTA is an umbrella company reimagining the R&D model and leveraging asset centricity at scale (ten... More

UPDATE: Jefferies Starts Centessa Pharmaceuticals (CNTA) at Buy

June 22, 2021 12:24 AM EDT

(Updated - June 22, 2021 7:53 AM EDT)

Jefferies analyst Eun Yang initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $35.00.

The analyst commented, "As a holding company with 10 distinct subsidiaries, CNTA's broad pipeline in diverse therapeutic... More